Effects of perhexiline on symptomatic and hemodynamic responses to exercise in patients with angina pectoris.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001161:Arteriosclerosis / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D002404:Catheterization; D002986:Clinical Trials as Topic; D003326:Coronary Circulation / Q000187:drug effects; D004417:Dyspnea; D005221:Fatigue; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D005996:Nitroglycerin / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D010480:Perhexiline / Q000008:administration & dosage / Q000627:therapeutic use; D005082:Physical Exertion / Q000187:drug effects*; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010880:Piperidines; D010919:Placebos; D014665:Vasodilator Agents; D005996:Nitroglycerin; D010480:Perhexiline